Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Data Validate 3x/Week MS Injections

September 12, 2014 7:00 am | News | Comments

Teva Pharmaceutical Industries Ltd. announced new data from the open-label Phase IIIb GLatiramer Acetate low frequenCy safety and patIent ExpeRience (GLACIER) study, comparing the safety and tolerability of three-times-a-week COPAXONE (glatiramer acetate injection) 40 mg to daily COPAXONE 20 mg in patients with relapsing-remitting multiple sclerosis (RRMS). 

TOPICS:

Using Antibiotics to Negate Heart Side Effects

September 12, 2014 7:00 am | News | Comments

A research team from the University of Bristol is looking at whether an antibiotic has the potential to prevent or treat irregular heartbeats brought on by other medicines. A research team will study whether low levels of the antibiotic erythromycin can block negative side effects, and will further investigate the mechanisms involved.

TOPICS:

University Working Toward Long-Acting HIV Drugs

September 12, 2014 7:00 am | News | Comments

HIV drugs that only need to be taken once a month are to be developed at the University of Liverpool in a bid to overcome the problem of "pill fatigue." To help address the problem, scientists are developing injections that provide therapeutic exposure to the drugs for at least a month and may replace daily tablets in some patients.

TOPICS:
Advertisement

SEM for 3-D Volume Imaging of Cells and Tissues

September 11, 2014 3:53 pm | Product Releases | Comments

The Teneo VS scanning electron microscope (SEM) from FEI offers a VolumeScope capability for life science applications. 

Our Microbes Are a Rich Source of Drugs

September 11, 2014 3:08 pm | News | Comments

Bacteria that normally live in and upon us have genetic blueprints that enable them to make thousands of molecules that act like drugs, and some of these molecules might serve as the basis for new human therapeutics, according to a new study. Read more...

TOPICS:

Compound Protects Brain Cells After TBI

September 11, 2014 3:03 pm | News | Comments

A new class of compounds has now been shown to protect brain cells from the type of damage caused by blast-mediated traumatic brain injury (TBI). Read more...                           

TOPICS:

Biogen's Phase 3 Tecfidera Trial Shows Positive 5-Year MS Data

September 11, 2014 2:57 pm | News | Comments

Biogen Idec announced that five-year results from the ENDORSE Phase 3 extension study show Tecfidera (dimethyl fumarate) provides strong and sustained efficacy in a broad range of people living with relapsing-remitting multiple sclerosis (RRMS). Read more...

TOPICS:

FDA Approves New Indication for the Use of Xtandi

September 11, 2014 2:51 pm | News | Comments

Astellas Pharma and Medivation announced that FDA approved a new indication for the use of Xtandi (enzalutamide) capsules to treat patients with metastatic castration-resistant prostate cancer (CRPC). Read more...           

TOPICS:
Advertisement

Many Hospitals Use Too Many Antibiotics, Study Says

September 11, 2014 2:46 pm | by Mike Stobbe, AP Medical Writer | News | Comments

Doctors in many U.S. hospitals are unnecessarily prescribing multiple antibiotics for several days when just one would do the job, a new study suggests. Read more...                         

TOPICS:

Two Anti-Ebola Vaccines in Historic Race

September 11, 2014 2:41 pm | by Cynthia Fox, Science Editor | Articles | Comments

One of the most rapidly fast-tracked vaccines in history— an anti-Ebola “ChAd3” vaccine— just started clinical trial in humans, and may be done as soon as November. But a second fast-tracked anti-Ebola vaccine— called an “rVSV” vaccine— is hot on its heels. Read more...

TOPICS:

Sanofi Posts Promising Trial Results for MS Drug

September 11, 2014 11:02 am | News | Comments

Sanofi and its subsidiary Genzyme announced positive interim results from the second year of the extension study of Lemtrada (alemtuzumab) for multiple sclerosis. Read more...                      

TOPICS:

CRUK, Asterias Biotherapeutics Partner on Lung Cancer Vaccine Trial

September 11, 2014 10:51 am | News | Comments

Cancer Research UK and Cancer Research Technology have reached an agreement with Asterias Biotherapeutics Inc. to take forward Asterias' novel immunotherapy treatment AST-VAC2 into clinical trials in subjects with non-small cell lung cancer. Read more...

TOPICS:

Relmada Files Clinical Trial App for D-Methadone in Canada

September 11, 2014 10:40 am | News | Comments

Relmada Therapeutics Inc. announced that it has filed a Clinical Trial Application (CTA) with Heath Canada to conduct two pharmacokinetic studies with d-methadone. Read more...                      

TOPICS:

7 U.S.-Based Researchers Share $1.3M Eyesight Prize

September 11, 2014 10:37 am | News | Comments

Seven U.S.-based researchers are sharing a prize of 1 million euro ($1.3 million) from a Portuguese foundation for their work developing treatment for angiogenic diseases of the retina, the leading cause of blindness in the developed world. Read more...

TOPICS:

FDA Approves Weight-Loss Drug Contrave

September 11, 2014 9:57 am | News | Comments

U.S. regulators are greenlighting a new weight-loss drug called Contrave, the third in a string of approvals for anti-obesity treatments. The drug was developed by Orexigen Therapeutics Inc., based in La Jolla, California. Read more...      

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading